Flavoxate Hydrochloride – Evidence‑Based Recommendations

Contraindications

• Urinary obstruction, severe hepatic impairment, gastrointestinal obstruction/ileus, and gastrointestinal hemorrhage are absolute contraindications to flavoxate therapy because the drug may exacerbate retention or impair metabolism. 1
• Hypersensitivity to flavoxate or any excipient precludes its use. 2

Safety Profile & Tolerability

• Flavoxate does not increase post‑void residual urine volume in the vast majority of patients, distinguishing it from anticholinergic agents that commonly cause urinary retention. 1
• In older adults (≥ 75 years), flavoxate’s lack of anticholinergic activity avoids cognitive impairment, dry mouth, constipation, and urinary retention, making it a safer pharmacologic option for this population. 1

Guideline Context

• The American Urological Association (AUA) and the Society of Urodynamics, Female Urology and Pelvic Reconstructive Surgery (SUFU) recommend behavioral therapy as first‑line and antimuscarinics as second‑line for overactive bladder; flavoxate is presented as a non‑anticholinergic pharmacologic alternative for patients who cannot tolerate antimuscarinic side effects or have contraindications. 2

Long‑Term Management

• After achieving symptom control, the effective flavoxate dose should be continued long‑term with periodic reassessment of urinary symptoms and residual volumes to ensure ongoing safety and efficacy. 1